PRNewsWire
23 Dec 2025, 16:06 UTC · 41w ago
Impact · against what's priced in
The news is materially negative for Skye Bioscience as it details a failed primary endpoint for nimacimab and a subsequent 60% collapse in stock price. The filing of a federal securities class action lawsuit further increases the company's regulatory and financial risk profile.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish
Skye Bioscience's nimacimab monotherapy arm failed to achieve its primary endpoint of weight loss in the Phase 2a CBeyond study.
So whatFailure of a primary endpoint in a clinical trial for a key drug candidate typically leads to a significant loss of valuation and commercial viability.
More negative than 99% of claims this week
A federal securities class action lawsuit has been filed against Skye Bioscience alleging executives made false or misleading statements regarding nimacimab's effectiveness.
Continue reading
5 related stories
The Phase 2a CBeyond study failed its primary weight loss endpoint, and the company now faces a federal securities class action lawsuit alleging misleading statements about nimacimab's effectiveness.
Read from the article alone
Scored by the NIS engine · methodology.
Search tags
More negative than 95% of claims this week
Preliminary pharmacokinetic analysis of nimacimab showed lower than expected drug exposure, suggesting a need for higher dosing.
More negative than 86% of claims this week
Which stocks this story touches
More negative than 95% of ticker scores this week
The company is facing a federal securities class action lawsuit following a 60% stock price drop due to a failed clinical trial endpoint.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
6h ago
−78.0%
Price agrees with the score
$1.62 vs $7.36 close before publication (Dec 22) · not market-adjusted
SKYE chart →
